Medical Device Network on MSN
Valar Labs hits US first with breakthrough designation for AI bladder cancer test
Valar Labs’ Vesta Bladder Risk Stratify Dx generates risk assessments for bladder cancer patients by analysing stained ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Valar Labs, the developer of computational histology AI tests for predicting response to cancer therapies, announced new data today which is being presented on ...
The assay delivers a risk score that can help clinicians to tailor treatment intensity to a patient's risk of disease progression.
Vesta Bladder Risk Stratify Dx applies Valar Labs' proprietary AI foundation models to standard hematoxylin and eosin (H&E) stained pathology slides-the slides produced as part of routine clinical ...
Early detection of bladder cancer can improve clinical outcomes and survival rates, similar to other cancers. One current area of research involves looking at cell mutations in areas where cancer may ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Valar Labs, the developer of computational histology AI (CHAI) tests for predicting response to cancer therapies, announced a $22 million Series A financing. The ...
Share on Pinterest A new urine test may enable more personalized treatment for bladder cancer. Image credit: SolStock/Getty Images A new urine-based test can detect minimal residual bladder cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results